An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

  title={An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates},
  author={Nerea Zabaleta and Wenlong Dai and Urja Bhatt and Jessica A. Chichester and Julio C. Sanmiguel and Reynette Estelien and Kristofer T. Michalson and Cheikh Diop and Dawid Maciorowski and Wenbin Qi and Elissa M. Hudspeth and Allison Cucalon and Cecilia Dyer and Maria Betina Pampena and James J. Knox and Regina C. LaRocque and Richelle C. Charles and Dan Li and Maya Kim and Abigail Sheridan and Nadia Storm and Rebecca I Johnson and Jared Feldman and Blake Marie Hauser and Aisling Ryan and Eric Zinn and Dione T. Kobayashi and Ruchi Chauhan and Marion McGlynn and Edward T. Ryan and Aaron G. Schmidt and Brian Price and Anna N. Honko and Anthony Griffiths and Sam Yaghmour and R. Hodge and Michael R. Betts and Mason W Freeman and James M. Wilson and Luk H. Vandenberghe},
  journal={Cell Host \& Microbe},
  pages={1437 - 1453.e8}
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and are easily delivered. Here, AAVCOVID-1, an adeno-associated viral (AAV), Spike gene-based vaccine candidate demonstrates potent immunogenicity in mouse and nonhuman primates following a single injection and confers complete protection from SARS-CoV-2… Expand


Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates is demonstrated and vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. Expand
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
A replication-incompetent adenovirus based vaccine expressing SARS-CoV-2 spike is generated, protection from infection in non-human primates is shown, and the immune response after intramuscular and intranasal vaccination is analyzed. Expand
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
The quality of immune responses triggered and the rapid kinetics by which protective immunity can be mounted already after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate. Expand
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Intranasal administration of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein is a candidate for preventing SARS-CoV-2 infection and transmission, and curtailing pandemic spread. Expand
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
The initial evaluation in mice of two updated COVID-19 mRNA vaccines designed to target emerging SARS-CoV-2 variants demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1. Expand
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity. Expand
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels. Expand
A Thermostable mRNA Vaccine against COVID-19
A lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (termed ARCoV) is developed and is currently being evaluated in phase 1 clinical trials. Expand
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
The efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on Spike (S) glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are described, positioning MRT5500 as a viable vaccine candidate for clinical development against COVID-19. Expand
Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease. Expand